Repare Therapeutics Inc.
RPTX
$1.36
$0.118.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -374.88% | -5.57% | |||
| Gross Profit | 374.88% | 2.07% | |||
| SG&A Expenses | 37.17% | -22.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.62% | -9.24% | |||
| Operating Income | 11.62% | 6.63% | |||
| Income Before Tax | 15.48% | 1.53% | |||
| Income Tax Expenses | -100.00% | 48.77% | |||
| Earnings from Continuing Operations | 16.67% | 1.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.67% | 1.06% | |||
| EBIT | 11.62% | 6.63% | |||
| EBITDA | 11.71% | 6.69% | |||
| EPS Basic | 16.79% | 1.07% | |||
| Normalized Basic EPS | 11.16% | 5.97% | |||
| EPS Diluted | 16.79% | 1.07% | |||
| Normalized Diluted EPS | 11.16% | 5.97% | |||
| Average Basic Shares Outstanding | 0.14% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.14% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||